Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 24 FE versus NORLESTRIN 21 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 24 FE versus NORLESTRIN 21 2 5 50.
GILDESS 24 FE vs NORLESTRIN 21 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone provides contraceptive effect primarily by suppression of gonadotropins (FSH and LH), inhibition of ovulation, and alterations in cervical mucus and endometrium. Drospirenone has antimineralocorticoid activity and antiandrogenic properties.
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
One tablet orally once daily for 24 days, followed by 4 days of placebo (iron tablets). The active tablets contain 0.8 mg norethindrone acetate and 0.025 mg ethinyl estradiol.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours); drospirenone: terminal half-life ~30-40 hours (mean ~32 hours). Clinical context: Steady-state achieved within 10 days for both components.
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Renal: ~50-60% as metabolites (ethinyl estradiol glucuronide and sulfate conjugates, drospirenone metabolites); fecal: ~40-50% (drospirenone metabolites); biliary excretion contributes to enterohepatic circulation.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive